Pfizer Tests Waters For Major Acquisitions (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

January 5, 2009 · Filed Under General, M&A 

It hasn’t taken long for the speculation machine to roll down Wall Street in 2009.  A report from the FT over the weekend shows that Pfizer Inc. (NYSE: PFE) is willing to acquire some large rivals.  We believe that this is a mere testing of the waters by the company now that its troubles have been persistent, but we also gave a whole list of these stocks in pharma and biotech which we feel are large enough to make an impact at the company.  You can see our full synopsis on this at 24/7 Wall St. and here is the list of the names we included:

Stock (Ticker)                              MktCap
Amgen Inc. (AMGN)                     $62.5B
Wyeth (WYE)                                 $51.1B
Gilead Sciences Inc. (GILD)          $47.5B
Bristol-Myers Squibb Co. (BMY)   $47.3B
Eli Lilly & Co. (LLY)                      $46.1B
Schering-Plough Corp. (SGP)       $28.2B
Celgene Corporation (CELG)        $25.9B
Genzyme Corp. (GENZ)                $18.4B
Biogen Idec Inc. (BIIB)                  $14.1B

JON OGG

January 5, 2009

Tags: , , , , , , , , , , , , ,

Comments

Comments are closed.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed